Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AREDS II update

This article was originally published in The Tan Sheet

Executive Summary

The National Eye Institute has enrolled 2,907 people aged 50 to 85 years with high risk of advanced macular degeneration to participate in the Age Related Eye Disease Study II, and researchers expect to complete enrollment by April, according to Dr. Traci Clemons at the SupplySide West trade show in Las Vegas Nov. 6. Clemons, senior statistician for the EMMES Corporation, the firm overseeing the study, updated seminar attendees on the the study's progress, which aims to evaluate the efficacy of lutein and zeanxanthin and/or lutein and zeanxanthin in combination with omega-3 fatty acids on progression to AMD (1"The Tan Sheet" Jan. 9, 2006, In Brief). Researchers will enroll approximately 4,000 subjects and conclude the study in 2013, five years after the last patient is enrolled...

You may also be interested in...

NIH lutein study

The second Age-Related Eye Disease Study (AREDS II) is slated to begin in Spring 2006, according to its sponsor, the National Eye Institute. The Phase III clinical trial will investigate whether oral supplementation with lutein (10 mg/day) and zeaxanthin (2 mg/day) and/or lutein and zeaxanthin in combination with omega-3 fatty acids (1 g/day) will slow the progression of age-related macular degeneration (AMD) when compared to placebo. Participants will be at moderate to high risk of AMD. The supplements' effect on cataract surgery also will be examined. To date, more than $4 mil. in funding has been awarded. The study builds off the first AREDS, which found that high-dose combination of antioxidants and zinc can lower the risk of developing advanced AMD in high-risk patients (1"The Tan Sheet" Oct. 15, 2001, p. 3)...

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts